In yet another hint of policy changes that are afoot to address drug prices, the U.S. Department of Health and Human Services (HHS) wants to delay implementation of a final rule that calculates ceiling prices for the 340B Drug Pricing Program and clarifies the civil money penalties drug companies will face for overcharging safety net health care providers for covered outpatient drugs.